ZA202207450B - Kras mutant protein inhibitors - Google Patents

Kras mutant protein inhibitors

Info

Publication number
ZA202207450B
ZA202207450B ZA2022/07450A ZA202207450A ZA202207450B ZA 202207450 B ZA202207450 B ZA 202207450B ZA 2022/07450 A ZA2022/07450 A ZA 2022/07450A ZA 202207450 A ZA202207450 A ZA 202207450A ZA 202207450 B ZA202207450 B ZA 202207450B
Authority
ZA
South Africa
Prior art keywords
mutant protein
protein inhibitors
kras mutant
kras
inhibitors
Prior art date
Application number
ZA2022/07450A
Other languages
English (en)
Inventor
Li Amin
Li Sujing
Wang Peng
DANG Chaojie
Liu Dan
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Publication of ZA202207450B publication Critical patent/ZA202207450B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA2022/07450A 2019-12-19 2022-07-05 Kras mutant protein inhibitors ZA202207450B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019126687 2019-12-19
CN2020070885 2020-01-08
CN2020073723 2020-01-22
CN2020078565 2020-03-10
PCT/CN2020/137497 WO2021121367A1 (en) 2019-12-19 2020-12-18 Kras mutant protein inhibitors

Publications (1)

Publication Number Publication Date
ZA202207450B true ZA202207450B (en) 2023-04-26

Family

ID=76478185

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2022/07450A ZA202207450B (en) 2019-12-19 2022-07-05 Kras mutant protein inhibitors
ZA2022/08783A ZA202208783B (en) 2019-12-19 2022-08-05 Kras mutant protein inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2022/08783A ZA202208783B (en) 2019-12-19 2022-08-05 Kras mutant protein inhibitors

Country Status (18)

Country Link
US (3) US11180506B2 (cg-RX-API-DMAC7.html)
EP (1) EP4077326A4 (cg-RX-API-DMAC7.html)
JP (1) JP7644517B2 (cg-RX-API-DMAC7.html)
KR (1) KR102958327B1 (cg-RX-API-DMAC7.html)
CN (4) CN113651814B (cg-RX-API-DMAC7.html)
AU (1) AU2020404319B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022011421A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165238A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001670A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022010098A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220351A (cg-RX-API-DMAC7.html)
IL (1) IL293962B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022007527A (cg-RX-API-DMAC7.html)
PE (1) PE20230161A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551503A1 (cg-RX-API-DMAC7.html)
TW (1) TWI871397B (cg-RX-API-DMAC7.html)
WO (1) WO2021121367A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202207450B (cg-RX-API-DMAC7.html)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN111484477B (zh) * 2019-01-29 2022-07-08 博瑞生物医药(苏州)股份有限公司 一种苯并吡啶酮杂环化合物及其用途
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
CA3165238A1 (en) * 2019-12-19 2021-06-24 Jacobio Pharmaceuticals Co., Ltd. Kras mutant protein inhibitors
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
CN114671866A (zh) * 2020-12-25 2022-06-28 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
TW202214630A (zh) * 2020-09-12 2022-04-16 大陸商成都倍特藥業股份有限公司 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2022066805A1 (en) 2020-09-23 2022-03-31 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
AR125835A1 (es) * 2021-05-12 2023-08-16 Jacobio Pharmaceuticals Co Ltd Novedosas formas del compuesto i y uso de las mismas
EP4378478A4 (en) 2021-07-27 2025-11-12 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
CN115894520A (zh) * 2021-09-23 2023-04-04 上海和誉生物医药科技有限公司 一种大环k-ras g12c抑制剂及其制备方法和在药学上的应用
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN116327956B (zh) * 2022-04-01 2025-11-28 劲方医药科技(上海)股份有限公司 药物组合物、其用途及癌症的治疗方法
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR102724980B1 (ko) 2022-09-21 2024-10-31 한화솔루션 주식회사 탠덤 태양전지 및 이의 제조방법
US20260137665A1 (en) 2022-10-11 2026-05-21 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
AU2023377064A1 (en) 2022-11-09 2025-05-22 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
WO2025036470A1 (en) * 2023-08-17 2025-02-20 Jacobio Pharmaceuticals Co., Ltd. Use of compound a for treating a cancer
EP4761734A1 (en) * 2023-08-17 2026-06-24 Jacobio Pharmaceuticals Co., Ltd. A pharmaceutical combination and use thereof
KR20260104082A (ko) 2023-09-29 2026-07-03 디3 바이오 (우씨) 컴퍼니, 리미티드 암의 치료에 사용하기 위한 wx-001 또는 그의 유도체와 kras g12c 억제제의 조합물
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078440B2 (en) 2010-12-16 2015-07-14 Bayer Intellectual Property Gmbh 6-(2-aminophenyl)picolinates and their use as herbicides
WO2015058084A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
US10892525B2 (en) 2016-06-29 2021-01-12 University Of Kentucky Research Foundation Rechargeable batteries including high-voltage cathode and redox shuttle conferring overcharge protection
JP2019529484A (ja) * 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Kras g12c変異体タンパク質の阻害剤
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
UA127968C2 (uk) * 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
CA3082579A1 (en) * 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
SG10202102462SA (en) * 2018-01-19 2021-04-29 Medshine Discovery Inc Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
AU2019284472B2 (en) * 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
JP7369719B2 (ja) * 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド KRas G12C阻害剤及びそれを使用する方法
CA3165238A1 (en) * 2019-12-19 2021-06-24 Jacobio Pharmaceuticals Co., Ltd. Kras mutant protein inhibitors

Also Published As

Publication number Publication date
CN113651814A (zh) 2021-11-16
EP4077326A4 (en) 2024-04-24
IL293962B2 (en) 2025-10-01
IL293962A (en) 2022-08-01
IL293962B1 (en) 2025-06-01
KR20220119088A (ko) 2022-08-26
CN115192577B (zh) 2024-03-29
TW202128691A (zh) 2021-08-01
CN113651814B (zh) 2022-06-17
JP2023506532A (ja) 2023-02-16
US20210292331A1 (en) 2021-09-23
CN114349750A (zh) 2022-04-15
PE20230161A1 (es) 2023-02-01
US12195473B2 (en) 2025-01-14
CO2022010098A2 (es) 2022-10-11
WO2021121367A1 (en) 2021-06-24
AU2020404319B2 (en) 2026-01-15
ZA202208783B (en) 2024-01-31
KR102958327B1 (ko) 2026-04-27
US20220213109A1 (en) 2022-07-07
JP7644517B2 (ja) 2025-03-12
EP4077326A1 (en) 2022-10-26
US20230011726A1 (en) 2023-01-12
AU2020404319A1 (en) 2022-08-18
US11180506B2 (en) 2021-11-23
CL2022001670A1 (es) 2023-03-17
CA3165238A1 (en) 2021-06-24
PH12022551503A1 (en) 2023-04-24
CN113454083A (zh) 2021-09-28
CR20220351A (es) 2022-10-31
CN115192577A (zh) 2022-10-18
US11787811B2 (en) 2023-10-17
BR112022011421A2 (pt) 2022-08-30
MX2022007527A (es) 2022-07-19
TWI871397B (zh) 2025-02-01

Similar Documents

Publication Publication Date Title
EP4077326A4 (en) KRAS MUTANT PROTEIN INHIBITORS
IL304534A (en) kras g12c inhibitors
ZA202205938B (en) Small molecule inhibitors of kras g12c mutant
ZA202202362B (en) Kras g12d inhibitors
EP3908283A4 (en) KRAS G12C INHIBITORS
IL288200A (en) kras g12c inhibitors and their use
EP4031542A4 (en) KRAS G12C MUTANT SMALL MOLECULE INHIBITORS
SMT202500146T1 (it) Inibitori di parp1
HUS2400019I1 (hu) KRas G12C inhibotorok
IL287767A (en) cdk inhibitors
IL276813A (en) Arginase inhibitors
IL289622A (en) bcl-2 protein inhibitors
ZA202106284B (en) Rad51 inhibitors
IL289863A (en) enzyme inhibitors
IL289914A (en) enzyme inhibitors
IL289778A (en) enzyme inhibitors
IL289783A (en) enzyme inhibitors
EP3929284A4 (en) PHYTASE MUTANT
HK40075881A (en) Kras mutant protein inhibitors
GB201905779D0 (en) Pcsk9 inhibitors for neuropathy
HK40055500A (en) Kras g12c inhibitors
GB202111043D0 (en) Protein interaction inhibitors
GB202110970D0 (en) Protein interaction inhibitors
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors